- Global Pharma News & Resources

Interleukin-2 (IL-2) Receptor Agonist Pipeline Insight, 2018 Report -

The "Interleukin-2 (IL-2) Receptor Agonist -Pipeline Insight, 2018" drug pipelines has been added to's offering.

'Interleukin-2 (IL-2) Receptor Agonist - Pipeline Insight, 2018' reportoffers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-2 (IL-2) Receptor Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Interleukin-2 (IL-2) Receptor Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Interleukin-2 (IL-2) Receptor Agonist

The report assesses the active Interleukin-2 (IL-2) Receptor Agonist pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report:

  • Provides a snapshot of the therapeutics pipeline activity for Interleukin-2 (IL-2) Receptor Agonist
  • Features the Interleukin-2 (IL-2) Receptor Agonist pipeline across the complete product development cycle including all clinical and non-clinical stages
  • Offers detailed therapeutic product profiles of Interleukin-2 (IL-2) Receptor Agonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
  • Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across Interleukin-2 (IL-2) Receptor Agonist

Reasons to Purchase:

  • Establish a comprehensive understanding of the current pipeline scenario across Interleukin-2 (IL-2) Receptor Agonist to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Interleukin-2 (IL-2) Receptor Agonist research & development (R&D)
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify and understand the sought after therapy areas and indications for Interleukin-2 (IL-2) Receptor Agonist
  • Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Interleukin-2 (IL-2) Receptor Agonist to enhance and expand business potential and scope
  • Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
  • Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

Key Topics Covered:

1. Report Introduction

2. Interleukin-2 (IL-2) Receptor Agonist - Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Interleukin-2 (IL-2) Receptor Agonist

4. Comparative Analysis

5. Interleukin-2 (IL-2) Receptor Agonist Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

Other product profiles in the detailed report..

6. Interleukin-2 (IL-2) Receptor Agonist Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Bayer
  • Philogen
  • Carlina Technologies
  • EMD Serono
  • Merck Serono
  • Pfizer
  • Celgene Corporation
  • Nanogen Biopharmaceutical Co
  • XEME Biopharma
  • Micromet Inc
  • Medicenna Therapeutics
  • Nektar Therapeutics

For more information about this drug pipelines report visit

View source version on

Editor Details

Last Updated: 30-Nov-2018